Showing results (1991-2000 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|November 1, 1992
Maintenance therapy with interferon alfa 2b in patients with diffuse large cell lymphomaA Avilés, J C Díaz-Maqueo, E L García, et al.
Investigational New Drugs|May 4, 2005
Phase II trial of dolastatin-10 in patients with advanced breast cancerEdith A Perez, David W Hillman, Paul A Fishkin, et al.
Investigational New Drugs|November 6, 2004
Inhibition of lymphocyte activation and function by the prenylation inhibitor L-778,123Ming-Sing Si, Bruce A Reitz, Dominic C Borie
Investigational New Drugs|November 6, 2004
Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjectsAimee K Bence, Eric B Anderson, Maqbool A Halepota, et al.
Investigational New Drugs|November 6, 2004
Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumorsBasil F El-Rayes, Dina Ibrahim, Anthony F Shields, et al.
Investigational New Drugs|August 13, 2005
Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: results of a prospective randomized phase II studyEmilio Esteban, Joaquin Fra, Yolanda Fernández, et al.
Investigational New Drugs|April 1, 1992
Phase II trial of didemnin-B in advanced epithelial ovarian cancer. A Southwest Oncology Group studyJ M Cain, P Y Liu, D E Alberts, et al.
Investigational New Drugs|September 1, 2005
Flutamide in unresectable pancreatic adenocarcinoma: a randomized, double-blind, placebo-controlled trialSanjay Singh Negi, Anil Agarwal, Adarsh Chaudhary
Investigational New Drugs|September 1, 2005
Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancerJ H Beumer, J M Rademaker-Lakhai, H Rosing, et al.
Investigational New Drugs|September 1, 2005
An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicinH Hirte, D Stewart, R Goel, et al.
Pageof 372